A5047507343- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Multiple Myeloma Research and Treatments
- Immune Cell Function and Interaction
- Lung Cancer Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- CAR-T cell therapy research
- Genetic factors in colorectal cancer
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Fungal Plant Pathogen Control
- Chromosomal and Genetic Variations
- Hematopoietic Stem Cell Transplantation
- Inflammatory Biomarkers in Disease Prognosis
- COVID-19 Clinical Research Studies
- MRI in cancer diagnosis
- Hemoglobinopathies and Related Disorders
- Retinal and Optic Conditions
- Inflammasome and immune disorders
- Synthesis and biological activity
- Chronic Lymphocytic Leukemia Research
- Radiomics and Machine Learning in Medical Imaging
Duke University Hospital
2022-2023
Duke Medical Center
2021-2023
University of Miami
2019-2021
Jackson Memorial Hospital
2020-2021
Medical University of South Carolina
2016
Natural Killer (NK) cell dysfunction is associated with poorer clinical outcome in cancer patients. What regulates NK tumor microenvironment not well understood. Here, we demonstrate that the human tumor-derived NKG2D ligand soluble MIC (sMIC) reprograms to secrete pro-tumorigenic cytokines diminished cytotoxicity and polyfunctional potential. Antibody clearing sMIC restores a normal cytotoxic effector functional state. We discovered selectively activates CBM-signalosome inflammatory...
Abstract Chronic graft-versus-host disease (cGVHD) is a debilitating, autoimmune-like syndrome that can occur after allogeneic hematopoietic stem cell transplantation. Constitutively activated B cells contribute to ongoing alloreactivity and autoreactivity in patients with cGVHD. Excessive tissue damage occurs transplantation exposes nucleic acids the extracellular environment. Recognition of endogenous within promote pathogenic B-cell activation. Therefore, we hypothesized cGVHD aberrantly...
### O1 IL-15 primes an mTOR-regulated gene-expression program to prolong anti-tumor capacity of human natural killer cells #### Andreas Lundqvist1, Vincent van Hoef1, Xiaonan Zhang1, Erik Wennerberg2, Julie Lorent1, Kristina Witt1, Laia Masvidal Sanz1, Shuo Liang1, Shannon Murray3, Ola Larsson1,
e15135 Background: While the use of monoclonal antibodies targeting PD-1 axis in metastatic non-small cell lung cancer (NSCLC) continues to expand since initial FDA approval 2015, factors predictive response still remain be determined. Mutation status may provide insight as which subgroups exhibit resistance checkpoint inhibitor therapy. Methods: We conducted a single center retrospective analysis patients with NSCLC treated at University Miami / Sylvester Comprehensive Cancer Center who...
e21547 Background: While genetic profiling has become standard of care for patients diagnosed with non-small cell lung cancer (NSCLC), next-generation sequencing (NGS) provides a wealth information about targetable mutations. Advances in testing have led to platforms that utilize tissue itself or extracellular circulating tumor DNA the blood, known as “liquid biopsy.” Methods: We identified 55 NSCLC who had undergone both and liquid biopsy, using Foundation One Guardant 360 at University...
Abstract Chimeric antigen receptor T (CAR-T) cells are an emerging approach for the treatment of hematologic and solid tumor malignancies. Axicabtagene ciloleucel (axi-cel) tisagenlecleucel were first FDA-approved CAR-T therapies targeting CD19 patients with relapsed/refractory (r/r) large B-cell lymphoma. Pivotal studies showed complete response (CR) rates 58% 40%, respectively, we sought to investigate if data similar our single-center results. We carried out a retrospective analysis...
SARS-CoV-2 emerged as a worldwide pandemic in late 2019 and initially was described primary respiratory illness. The clinical manifestations of COVID-19 are now known to encompass nearly all organ systems, including the central nervous system. We present case an allogeneic hematopoietic stem cell transplant recipient who recovered from documented infection later presented with symptoms meningitis. While cerebrospinal fluid analysis did not reveal any bacterial or viral etiologies, evidence...
e20507 Background: It is reported that about 20% of patients with resected NSCLC adenocarcinoma harbor an EGFR driver mutation in the United States. Up to recent approval osimertinib adjuvant setting for + based on ADAURA trial, routine molecular profiling early-stage lung cancer had not been standard care. We hypothesize there a significant proportion unknown status who could benefit from treatment are missed our current testing practices. Methods: performed retrospective analysis Stage...
Renal medullary carcinoma (RMC) is an extremely rare malignancy that has been described in younger male patients of African descent with a history sickle cell disease or trait. We describe rather unique case RMC older patient who initially presented acute on chronic urinary retention and concern for infection. Further investigation revealed hematuria long-standing microcytic anemia, the was found to have trait (SCT) as part workup unknown primary. Imaging findings interpreted hydronephrosis...
e21210 Background: Treatment of advanced non-small cell lung cancer with immune checkpoint inhibitors (ICI) has been shown to yield durable responses. High neutrophil-to-lymphocyte ratios (NLR), low lymphocyte-to-monocyte (LMR) and high platelet-to-lymphocyte (PLRs) have used as surrogates for increased levels inflammation in the tumor microenvironment that can predict progression response therapy. However, comparative prognostic role these markers account when immunotherapy is utilized not...
e21027 Background: Hispanic (H) patients with non-small cell lung cancer (NSCLC) tend to have more advanced disease at time of diagnosis and less likely receive treatment compared non-Hispanic white (NHW) Americans. While survival outcomes do not differ greatly, lower response rates immunotherapy targeted therapy known EGFR mutations. We sought determine if other common mutations present in NSCLC also demonstrate suboptimal responses NHW patients. Methods: performed a retrospective review...
e21219 Background: Mutations in BRAF oncogene have been identified about 2-4% of non-small cell lung cancer (NSCLC) patients. Combination tyrosine kinase inhibitors (TKI), dabrafenib and trametinib has shown improved enduring results both first line second setting. Given the rarity mutations, approval TKI, role Immune Checkpoint Inhibitors (ICI) still needs to be ascertained. Methods: We conducted a retrospective review 19 BRAF-mutant patients from 2013-2020 at University Miami....